IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have received an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $751.00.

A number of brokerages have recently weighed in on IDXX. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $566.79 on Tuesday. IDEXX Laboratories has a 1-year low of $504.56 and a 1-year high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $44.71 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 3.27 and a beta of 1.56. The stock’s fifty day simple moving average is $564.32 and its 200-day simple moving average is $635.65.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts predict that IDEXX Laboratories will post 14.68 earnings per share for the current fiscal year.

Institutional Trading of IDEXX Laboratories

A number of institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after purchasing an additional 15 shares during the last quarter. Harbour Investments Inc. boosted its position in IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares during the last quarter. CWA Asset Management Group LLC boosted its position in IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after purchasing an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. boosted its position in IDEXX Laboratories by 1.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after purchasing an additional 18 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC boosted its position in IDEXX Laboratories by 11.5% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after purchasing an additional 18 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.